Universität zu Köln

Sieg, Noelle, Naendrup, Jan-Hendrik, Goedel, Philipp, Balke-Want, Hyatt, Simon, Florian, Deckert, Martina, Gillessen, Sarah, Kreissl, Stefanie, Broeckelmann, Paul J., Borchmann, Peter, von Tresckow, Bastian and Heger, Jan-Michel (2021). Treatment patterns and disease course of previously untreated Primary Central Nervous System Lymphoma: Feasibility of MTX-based regimens in clinical routine. Eur. J. Haematol., 107 (2). S. 202 - 211. HOBOKEN: WILEY. ISSN 1600-0609

Full text not available from this repository.

Abstract

Background Primary central nervous system lymphoma (PCNSL) is a rare type of aggressive lymphoma of the central nervous system. Treatment strategies improved significantly over the past decades differ regionally but mainly consist of rituximab and high-dosed methotrexate (MTX)-based therapies. Methods We assessed clinical outcomes of 100 patients with newly diagnosed PCNSL between 2010-2020 at the University Hospital of Cologne, Germany. Results Patients were 23-88 years of age and either treated with MTX-based regimens (PRIMAIN, MARTA, MATRix), individual regimens, or best supportive care, respectively. Overall response rates were generally high (66,7-83,8%), but different organ toxicities required dose adjustments in most groups. Two-year overall survival rates were 57,9% (PRIMAIN), 63,6% (MARTA), 65,4% (MATRix), and 37,5% (Other), respectively. Out of 9 patients suffering from relapse >12 months from primary diagnosis, 7 patients (77,8%) received methotrexate-based salvage therapy with 2-year overall survival of 4/6 patients (66,7%). Conclusion Although a relevant proportion of patients are not eligible for clinical trials due to age, performance status, or comorbidities, these results prove feasibility of different MTX-based treatment strategies in clinical routine. Even elderly patients displayed surprisingly favorable outcomes. However, with compromising organ toxicities, reduction of intensity should be part of strategies in future clinical trials.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Sieg, Noelle UNSPECIFIED UNSPECIFIED UNSPECIFIED Naendrup, Jan-Hendrik UNSPECIFIED UNSPECIFIED UNSPECIFIED Goedel, Philipp UNSPECIFIED UNSPECIFIED UNSPECIFIED Balke-Want, Hyatt UNSPECIFIED UNSPECIFIED UNSPECIFIED Simon, Florian UNSPECIFIED UNSPECIFIED UNSPECIFIED Deckert, Martina UNSPECIFIED UNSPECIFIED UNSPECIFIED Gillessen, Sarah UNSPECIFIED UNSPECIFIED UNSPECIFIED Kreissl, Stefanie UNSPECIFIED UNSPECIFIED UNSPECIFIED Broeckelmann, Paul J. UNSPECIFIED UNSPECIFIED UNSPECIFIED Borchmann, Peter UNSPECIFIED UNSPECIFIED UNSPECIFIED von Tresckow, Bastian UNSPECIFIED UNSPECIFIED UNSPECIFIED Heger, Jan-Michel UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-587281
DOI:	10.1111/ejh.13639
Journal or Publication Title:	Eur. J. Haematol.
Volume:	107
Number:	2
Page Range:	S. 202 - 211
Date:	2021
Publisher:	WILEY
Place of Publication:	HOBOKEN
ISSN:	1600-0609
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language PRIMARY CNS LYMPHOMA; HIGH-DOSE METHOTREXATE; NON-HODGKINS-LYMPHOMA; PHASE-II; CHEMOTHERAPY; SURVIVAL; RADIOTHERAPY; MULTICENTER; THERAPY; TRIAL Multiple languages Hematology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/58728